Hello XXXX, I wanted to offer you a unique interview opportunity with top executives at Hua Medicine (HK:2552), the company that developed and brought to the market a new ‘smart’ drug that can send diabetes into remission. The drug dorzagliatin, marketed as HuaTangNing in China, represents a massive leap forward in how diabetes can be treated. Dorzagliatin is an allosteric glucokinase (GK) activator approved in China in September 2022 to treat diabetes. Dorzagliatin was the focus of a recent scientific paper that built on voluminous amounts of past research, publications, and large clinical trials. On Aug. 17, Hua Medicine and its commercialization partner Bayer confirmed the achievement of a key development milestone payment of almost US$110 million. Along with sharing information about Hua Medicine’s strengthened cash position, I wanted to offer you the opportunity to interview Hua Medicine’s Chief Strategy Officer George Lin on the future of the company and the significance of new ‘smart’ treatments for diabetes, a disease that affects hundreds of millions of people around the world, and the very real possibility that now exists to send diabetes into remission. New developmentA new paper published in the influential journal Diabetes, Obesity and Metabolism relies on data from a 52-week study to show how patients with Type 2 diabetes that use HuaTangNing can achieve remission and maintain it after a year without the need to use other drugs. The paper titled “Diabetes remission in drug-naïve patients with type 2 diabetes after dorzagliatin treatment: A prospective cohort study” outlines the ability of HuaTangNing to help patients achieve blood glucose balance, leading to drug-free diabetes remission. Given the rising incidence of diabetes around the world, HuaTangNing could be a game changer in the treatment of diabetes. Currently, it is only available for sale in mainland China. More details of the study can be found here. ContactTo learn more about Hua Medicine and HuaTangNing (dorzagliatin) or to arrange an interview with Hua Medicine CEO Dr. Chen LI or CSO George Lin, please contact: hua.medicine@bahati.com.hk. Dorzagliatin: A game changer• Technically, dorzagliatin is a novel allosteric glucokinase (GK) activator. • The GK enzyme acts as a glucose ‘sensor’ to monitor blood sugar levels and is effectively the central controller of the body in maintaining healthy glucose levels. As a glucose sensor, the GK enzyme, among other things, signals to the pancreas to release insulin when glucose levels are rising. Insulin, in turn, assists cells throughout the body to absorb glucose from the blood. • The GK ‘sensor’ does not work efficiently in Type 2 diabetes patients.• Dorzagliatin is a “smart” drug that improves GK’s ability to sense glucose better regulate insulin production. • Dorzagliatin is the first drug approved in a major market that can address one of the root cause of Type 2 diabetes and with the potential to induce clinical remission. • China’s National Medical Products Administration (NMPA) approved dorzagliatin at the end of September 2022 with a broad label for Type 2 diabetes patients, an emphasis on improving the beta cell function of patients. • The benefits dorzagliatin has already generated for patients in China has attracted considerable attention among the biopharma community. About Hua MedicineHua Medicine develops new and innovative drugs. We team up with top talent from around the world to develop breakthrough technologies and products that advance diabetes care. Hua Medicine (HKEx:2552) is based in Shanghai and listed in Hong Kong. Our cornerstone product, HuaTangNing (dorzagliatin tablets), could help millions of diabetic patients around the world. Dorzagliatin targets the glucose sensor glucokinase, restoring glucose sensitivity and stabilizing blood glucose imbalances. Approved in China, HuaTangNing can be used alone or as part of a combination to help people suffering from chronic kidney disease and Type 2 diabetes. Data from clinical studies showed this innovative drug has the potential to bring about clinical remission of diabetes.China’s National Medical Products Administration (NMPA) approved the commercialization of dorzagliatin in September 2022.
The drug dorzagliatin, marketed as HuaTangNing in China, represents a massive leap forward in how diabetes can be treated. Dorzagliatin is an allosteric glucokinase (GK) activator approved in China in September 2022 to treat diabetes. Dorzagliatin was the focus of a recent scientific paper that built on voluminous amounts of past research, publications, and large clinical trials. On Aug. 17, Hua Medicine and its commercialization partner Bayer confirmed the achievement of a key development milestone payment of almost US$110 million. Along with sharing information about Hua Medicine’s strengthened cash position, I wanted to offer you the opportunity to interview Hua Medicine’s Chief Strategy Officer George Lin on the future of the company and the significance of new ‘smart’ treatments for diabetes, a disease that affects hundreds of millions of people around the world, and the very real possibility that now exists to send diabetes into remission. New developmentA new paper published in the influential journal Diabetes, Obesity and Metabolism relies on data from a 52-week study to show how patients with Type 2 diabetes that use HuaTangNing can achieve remission and maintain it after a year without the need to use other drugs. The paper titled “Diabetes remission in drug-naïve patients with type 2 diabetes after dorzagliatin treatment: A prospective cohort study” outlines the ability of HuaTangNing to help patients achieve blood glucose balance, leading to drug-free diabetes remission. Given the rising incidence of diabetes around the world, HuaTangNing could be a game changer in the treatment of diabetes. Currently, it is only available for sale in mainland China. More details of the study can be found here. ContactTo learn more about Hua Medicine and HuaTangNing (dorzagliatin) or to arrange an interview with Hua Medicine CEO Dr. Chen LI or CSO George Lin, please contact: hua.medicine@bahati.com.hk. Dorzagliatin: A game changer• Technically, dorzagliatin is a novel allosteric glucokinase (GK) activator. • The GK enzyme acts as a glucose ‘sensor’ to monitor blood sugar levels and is effectively the central controller of the body in maintaining healthy glucose levels. As a glucose sensor, the GK enzyme, among other things, signals to the pancreas to release insulin when glucose levels are rising. Insulin, in turn, assists cells throughout the body to absorb glucose from the blood. • The GK ‘sensor’ does not work efficiently in Type 2 diabetes patients.• Dorzagliatin is a “smart” drug that improves GK’s ability to sense glucose better regulate insulin production. • Dorzagliatin is the first drug approved in a major market that can address one of the root cause of Type 2 diabetes and with the potential to induce clinical remission. • China’s National Medical Products Administration (NMPA) approved dorzagliatin at the end of September 2022 with a broad label for Type 2 diabetes patients, an emphasis on improving the beta cell function of patients. • The benefits dorzagliatin has already generated for patients in China has attracted considerable attention among the biopharma community. About Hua MedicineHua Medicine develops new and innovative drugs. We team up with top talent from around the world to develop breakthrough technologies and products that advance diabetes care. Hua Medicine (HKEx:2552) is based in Shanghai and listed in Hong Kong. Our cornerstone product, HuaTangNing (dorzagliatin tablets), could help millions of diabetic patients around the world. Dorzagliatin targets the glucose sensor glucokinase, restoring glucose sensitivity and stabilizing blood glucose imbalances. Approved in China, HuaTangNing can be used alone or as part of a combination to help people suffering from chronic kidney disease and Type 2 diabetes. Data from clinical studies showed this innovative drug has the potential to bring about clinical remission of diabetes.China’s National Medical Products Administration (NMPA) approved the commercialization of dorzagliatin in September 2022.
